Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth (Status and Outlook) 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2017-2028

2.1.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region 2017 VS 2022 VS 2028

2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type

2.2.1 Single-stranded AAV (ssAAV)

2.2.2 Self-complementary AAV (scAAV)

2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type

2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type (2017 VS 2022 VS 2028)

2.3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2017-2022)

2.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application

2.4.1 Hemophilia

2.4.2 Ophthalmology

2.4.3 Lysosomal Storage Disorders

2.4.4 Neurological Disorders

2.4.5 Others

2.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application

2.5.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application (2017 VS 2022 VS 2028)

2.5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2017-2022)

3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Player

3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Players

3.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2020-2022)

3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2020-2022)

3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Regions

4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions (2017-2022)

4.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2017-2022)

4.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2017-2022)

4.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2017-2022)

4.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2017-2022)

5 Americas

5.1 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2017-2022)

5.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022)

5.3 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2017-2022)

6.2 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022)

6.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country (2017-2022)

7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022)

7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Region (2017-2022)

8.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022)

8.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2023-2028)

10.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2023-2028)

10.1.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast

10.1.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast

10.1.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast

10.1.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast

10.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2023-2028)

10.2.1 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.2.2 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.2.3 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.2.4 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2023-2028)

10.3.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.2 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.3 Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.4 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.5 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.3.6 Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2023-2028)

10.4.1 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4.2 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4.3 UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4.4 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.4.5 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2023-2028)

10.5.1 Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5.2 South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5.3 Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5.4 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.5.5 GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast

10.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Type (2023-2028)

10.7 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Application (2023-2028)

11 Key Players Analysis

11.1 BioMarin Pharmaceutical

11.1.1 BioMarin Pharmaceutical Company Information

11.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.1.4 BioMarin Pharmaceutical Main Business Overview

11.1.5 BioMarin Pharmaceutical Latest Developments

11.2 Sangamo Therapeutics

11.2.1 Sangamo Therapeutics Company Information

11.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.2.4 Sangamo Therapeutics Main Business Overview

11.2.5 Sangamo Therapeutics Latest Developments

11.3 Amicus Therapeutics

11.3.1 Amicus Therapeutics Company Information

11.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.3.4 Amicus Therapeutics Main Business Overview

11.3.5 Amicus Therapeutics Latest Developments

11.4 Roche

11.4.1 Roche Company Information

11.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.4.4 Roche Main Business Overview

11.4.5 Roche Latest Developments

11.5 Pfizer

11.5.1 Pfizer Company Information

11.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.5.4 Pfizer Main Business Overview

11.5.5 Pfizer Latest Developments

11.6 NightstaRx

11.6.1 NightstaRx Company Information

11.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.6.4 NightstaRx Main Business Overview

11.6.5 NightstaRx Latest Developments

11.7 MeiraGTx

11.7.1 MeiraGTx Company Information

11.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.7.4 MeiraGTx Main Business Overview

11.7.5 MeiraGTx Latest Developments

11.8 Sarepta Therapeutics

11.8.1 Sarepta Therapeutics Company Information

11.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.8.4 Sarepta Therapeutics Main Business Overview

11.8.5 Sarepta Therapeutics Latest Developments

11.9 Neurocrine Biosciences

11.9.1 Neurocrine Biosciences Company Information

11.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.9.4 Neurocrine Biosciences Main Business Overview

11.9.5 Neurocrine Biosciences Latest Developments

11.10 Voyager Therapeutics

11.10.1 Voyager Therapeutics Company Information

11.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.10.4 Voyager Therapeutics Main Business Overview

11.10.5 Voyager Therapeutics Latest Developments

11.11 Asklepios Biopharmaceutical

11.11.1 Asklepios Biopharmaceutical Company Information

11.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2022)

11.11.4 Asklepios Biopharmaceutical Main Business Overview

11.11.5 Asklepios Biopharmaceutical Latest Developments

12 Research Findings and Conclusion

Table 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)

Table 2. Major Players of Single-stranded AAV (ssAAV)

Table 3. Major Players of Self-complementary AAV (scAAV)

Table 4. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)

Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022) & ($ Millions)

Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2017-2022)

Table 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)

Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022) & ($ Millions)

Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2017-2022)

Table 10. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2020-2022) & ($ Millions)

Table 11. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Player (2020-2022)

Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered

Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions 2017-2022 & ($ Millions)

Table 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Regions (2017-2022)

Table 18. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2017-2022) & ($ Millions)

Table 19. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country (2017-2022)

Table 20. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022) & ($ Millions)

Table 21. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2017-2022)

Table 22. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022) & ($ Millions)

Table 23. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2017-2022)

Table 24. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2017-2022) & ($ Millions)

Table 25. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2017-2022)

Table 26. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022) & ($ Millions)

Table 27. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2017-2022)

Table 28. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022) & ($ Millions)

Table 29. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2017-2022)

Table 30. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2017-2022) & ($ Millions)

Table 31. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country (2017-2022)

Table 32. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022) & ($ Millions)

Table 33. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2017-2022)

Table 34. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022) & ($ Millions)

Table 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2017-2022)

Table 36. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2017-2022) & ($ Millions)

Table 37. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2017-2022)

Table 38. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2017-2022) & ($ Millions)

Table 39. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2017-2022)

Table 40. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2017-2022) & ($ Millions)

Table 41. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2017-2022)

Table 42. Key Market Drivers & Growth Opportunities of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Table 43. Key Market Challenges & Risks of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Table 44. Key Industry Trends of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

Table 45. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Regions (2023-2028) & ($ Millions)

Table 46. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Regions (2023-2028)

Table 47. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2023-2028) & ($ Millions)

Table 48. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Type (2023-2028)

Table 49. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Application (2023-2028) & ($ Millions)

Table 50. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Application (2023-2028)

Table 51. BioMarin Pharmaceutical Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 52. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 53. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 54. BioMarin Pharmaceutical Main Business

Table 55. BioMarin Pharmaceutical Latest Developments

Table 56. Sangamo Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 57. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 58. Sangamo Therapeutics Main Business

Table 59. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 60. Sangamo Therapeutics Latest Developments

Table 61. Amicus Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 62. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 63. Amicus Therapeutics Main Business

Table 64. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 65. Amicus Therapeutics Latest Developments

Table 66. Roche Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 67. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 68. Roche Main Business

Table 69. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 70. Roche Latest Developments

Table 71. Pfizer Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 72. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 73. Pfizer Main Business

Table 74. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 75. Pfizer Latest Developments

Table 76. NightstaRx Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 77. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 78. NightstaRx Main Business

Table 79. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 80. NightstaRx Latest Developments

Table 81. MeiraGTx Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 82. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 83. MeiraGTx Main Business

Table 84. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 85. MeiraGTx Latest Developments

Table 86. Sarepta Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 87. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 88. Sarepta Therapeutics Main Business

Table 89. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 90. Sarepta Therapeutics Latest Developments

Table 91. Neurocrine Biosciences Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 92. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 93. Neurocrine Biosciences Main Business

Table 94. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 95. Neurocrine Biosciences Latest Developments

Table 96. Voyager Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 97. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 98. Voyager Therapeutics Main Business

Table 99. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 100. Voyager Therapeutics Latest Developments

Table 101. Asklepios Biopharmaceutical Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors

Table 102. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered

Table 103. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2020-2022)

Table 104. Asklepios Biopharmaceutical Main Business

Table 105. Asklepios Biopharmaceutical Latest Developments

List of Figures

Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate 2017-2028 ($ Millions)

Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2021

Figure 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Hemophilia

Figure 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Hemophilia (2017-2022) & ($ Millions)

Figure 9. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Ophthalmology

Figure 10. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Ophthalmology (2017-2022) & ($ Millions)

Figure 11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Lysosomal Storage Disorders

Figure 12. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Lysosomal Storage Disorders (2017-2022) & ($ Millions)

Figure 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Neurological Disorders

Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Neurological Disorders (2017-2022) & ($ Millions)

Figure 15. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Others

Figure 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Others (2017-2022) & ($ Millions)

Figure 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2021

Figure 18. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Player in 2021

Figure 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Regions (2017-2022)

Figure 20. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2017-2022 ($ Millions)

Figure 21. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2017-2022 ($ Millions)

Figure 22. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2017-2022 ($ Millions)

Figure 23. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2017-2022 ($ Millions)

Figure 24. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Value Market Share by Country in 2021

Figure 25. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Market Share by Type in 2021

Figure 26. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2021

Figure 27. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 28. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 29. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 30. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 31. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region in 2021

Figure 32. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2021

Figure 33. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 34. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 35. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 36. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 37. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 38. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 39. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country in 2021

Figure 40. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2021

Figure 41. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2021

Figure 42. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 43. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 44. UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 45. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 46. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 47. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region in 2021

Figure 48. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2021

Figure 49. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2021

Figure 50. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 51. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 52. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 53. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 54. GCC Country Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2017-2022 ($ Millions)

Figure 55. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 56. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 57. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 58. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 59. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 60. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 61. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 62. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 63. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 64. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 65. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 66. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 67. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 68. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 69. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 70. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 71. UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 72. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 73. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 74. Spain Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 75. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 76. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 77. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 78. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)

Figure 79. GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2023-2028 ($ Millions)